Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocardia Inc (NQ: BCDA )

1.860 +0.340 (+22.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 56,201
Open 1.530
Bid (Size) 1.780 (28)
Ask (Size) 2.470 (2)
Prev. Close 1.520
Today's Range 1.530 - 1.950
52wk Range 1.230 - 2.600
Shares Outstanding 20,219,087
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recap: BioCardia Q1 Earnings
 
Via Benzinga
BioCardia Earnings Preview
 
Via Benzinga

Performance

YTD
-14.29%
-14.29%
1 Month
-9.71%
-9.71%
3 Month
-14.68%
-14.68%
6 Month
+0.54%
+0.54%
1 Year
+10.71%
+10.71%

More News

Read More
BioCardia Earnings Perspective: Return On Capital Employed
Via Benzinga
Earnings Outlook For BioCardia
Via Benzinga
BioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study
Via Benzinga
$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
BioCardia's Return On Capital Employed Insights
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
BioCardia's Heart Failure Cell Therapy Shows 100% Survival At Two Years
Via Benzinga
Recap: BioCardia Q2 Earnings
Via Benzinga
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
From BioCardia, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022
Via Benzinga
Earnings Preview For BioCardia
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Via Benzinga
BioCardia Earnings Preview
Via Benzinga
Executives Buy Around $4M Of 5 Penny Stocks
Via Benzinga
Recap: BioCardia Q1 Earnings
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Via Benzinga
Earnings Preview For BioCardia
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Follow the Insiders and Buy the Dip in These 3 Stocks
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.